The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be. The quality of innovation coming out of labs, with 25 of
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the news announced today by Atelerix that it has been awarded a grant of £267,000 from Innovate UK. The grant will be used to develop gel stabilisation technologies, developed by Atelerix, with the first objective of extending the
The CRISPR Journal announces the publication of its August 2019 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. The Journal, led by
South Korea is seeking to ease legislative restrictions to allow research on breakthrough gene therapies using gene editing and other advanced gene correction tools. The Ministry of Health and Welfare said on Thursday it is revising the Bioethics Act to allow gene therapy research in this direction. Rep. Yoon Il-kyu of the ruling Democratic Party,
There’s hope a gene therapy being developed at the Australian National University could one day help save the eyesight of millions. The therapy is working on preventing the loss of eyesight from dry age-related macular degeneration (dry AMD). Dry AMD is a common disorder that is caused by damage to the macula – the part
Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would
Source Transparency Market Research Gene Therapy Market – Snapshot The global gene therapy market is expanding at an exponential pace due to promising therapeutic outcomes of gene therapy, high prevalence and rise in incidence of cancer, and large number of clinical research pipeline products. In terms of revenue, the market was valued at US$ 17.0
Source Global Data Gene therapy involves the delivery of complex treatments to patients. In recent years, there have been several promising clinical trial results within this field targeting an array of inherited neurodegenerative disorders, genetic diseases, and various cancers. Approvals based on these clinical trials have consequently encouraged interest in gene therapy from both industry
Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously. Everyone’s talking about CRISPR-Cas. This biotechnological method offers a relatively quick and easy way to manipulate single genes in cells, meaning they can be
Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments. Source NYT Spinal muscular atrophy is a condition often fatal by age 2. Babies with the disorder have a rare genetic mutation that prevents the nervous system from controlling certain muscles. As they grow to be toddlers, these children struggle to move their limbs,
